Spravato is NOT an appropriate option for this patient
In a patient with an ejection fraction of 30% and a history of seizures, esketamine (Spravato) is contraindicated due to cardiovascular risk and should be avoided.
Critical Cardiovascular Contraindication
The FDA labeling for Spravato explicitly warns that patients with cardiovascular conditions may be at increased risk of adverse effects related to blood pressure elevations 1. The drug causes significant increases in blood pressure, which is a primary safety concern 1.
For a patient with an EF of 30% (indicating moderate-to-severe heart failure):
- The hemodynamic stress from blood pressure elevations could precipitate acute decompensation
- The cardiovascular system has limited reserve to tolerate additional afterload
- Risk of mortality from cardiovascular events substantially outweighs potential psychiatric benefit
The FDA specifically lists aneurysmal vascular disease and cardiovascular conditions as areas requiring careful assessment before use 1. While heart failure with reduced ejection fraction is not an absolute contraindication in the labeling, the clinical reality is that patients with EF 30% have significantly compromised cardiac function that makes them high-risk for the blood pressure effects.
Seizure History Considerations
Regarding the seizure history, the evidence is more nuanced:
- Ketamine and esketamine have been studied in ECT (electroconvulsive therapy) contexts, where they may actually prolong seizure duration 2
- There is no absolute contraindication for seizure disorders in the FDA labeling 1
- However, the dissociative and CNS effects could theoretically lower seizure threshold
Alternative Recommendations
For this patient with treatment-resistant depression:
Safer alternatives include:
- Repetitive transcranial magnetic stimulation (rTMS), which has minimal cardiovascular effects and is not contraindicated in seizure disorders 3
- Optimization of oral antidepressant therapy with augmentation strategies
- ECT with careful anesthetic selection (though cardiovascular monitoring would still be critical) 2
If depression is severe with suicidal ideation:
- Hospitalization for safety
- Intensive medication optimization
- Consider rTMS as it has demonstrated efficacy in TRD with "only minimal and manageable adverse events" 3
Clinical Pitfall to Avoid
Do not be swayed by the 2022 VA/DoD guideline recommendation supporting esketamine for treatment-resistant depression 3. That recommendation does not account for individual patient contraindications. The guideline states esketamine should be considered "in patients who have not responded to several adequate pharmacologic trials" but assumes medically appropriate candidates. Your patient's EF of 30% fundamentally changes the risk-benefit calculation, prioritizing mortality risk over psychiatric benefit.
The supervised administration requirement exists precisely because of cardiovascular monitoring needs 1, but monitoring does not prevent the blood pressure elevation—it only allows for detection and management of complications that may already be life-threatening in a patient with severe systolic dysfunction.